Eugeroics

Classic stimulants act as substrates at the dopamine and norepinephrine transporters. They are carried into the terminal, they reverse the direction of transport, and they push transmitter out into the synapse whether or not the neuron is firing. That is why the effect is large, why it is euphoric, why it costs appetite and heart rate, and why it ends in a crash. See the dopaminergic system for the machinery involved.

Modafinil is a blocker, not a substrate, and a weak one. In transfected cells it inhibited dopamine uptake with an IC50 around 6.4 micromolar and norepinephrine uptake around 35.6 micromolar, with essentially no activity at the serotonin transporter ^[6]. Micromolar is a thousandfold weaker than the classic reuptake inhibitors, and the compound does not trigger release. What it does instead is occupy the transporter and let the brain's own firing set the tone. That is a genuine pharmacological difference and it plausibly explains the flatter subjective curve.

It does not, however, make the drug dopamine-independent, and three separate lines of evidence say so. Mice lacking the dopamine transporter gene are unresponsive to the wake-promoting effect of modafinil while remaining hypersensitive to caffeine ^[4]. In wild-type mice, a D1 antagonist or a D2 antagonist blocks the arousal effect at low doses, and D2 knockouts show a blunted response that a D1 antagonist then abolishes entirely ^[8]. And in living human brain, the transporter occupancy and the accumbens dopamine rise are both directly measurable ^[5]. Dopamine is not incidental to how this drug works; it is the route.

The practical comparison most people actually want is against caffeine, and it has been run. Fifty healthy adults were kept awake for 54 hours and then given placebo, modafinil at 100, 200 or 400 mg, or caffeine 600 mg. Modafinil at 200 and 400 mg significantly improved performance and alertness over placebo, especially through the early-morning circadian trough; so did caffeine, and the two were equivalent ^[11]. The authors concluded that modafinil offered no advantage over caffeine for sleep loss in otherwise healthy people. That is a useful piece of calibration to carry into any decision about an all-nighter.

One more asymmetry belongs here. Modafinil's advantage over caffeine is not potency, it is duration and evenness: a 12 to 15 hour half-life with dose-proportional kinetics ^[9] produces a long flat plateau rather than caffeine's shorter arc. That is the property people are usually buying, and it is also the property that makes an evening dose a mistake.

Put the evidence in order and a clear picture emerges. Modafinil occupies the dopamine transporter. Raised catecholamine tone then propagates into the hypothalamic systems that normally hold wakefulness open, so orexin neurons and the histaminergic tuberomammillary nucleus light up on Fos mapping ^[3] and histamine release goes up ^[7], but those look like consequences rather than targets. The comprehensive review of the preclinical literature reached the same conclusion: the effects on serotonin, glutamate, GABA, orexin and histamine may all be secondary to catecholamine actions, with some selectivity for cortical over subcortical sites ^[1].

The genuinely open question is why the subjective profile differs so much from a stimulant if the molecular story is a transporter block. Two partial answers are on the table and neither is settled. One is kinetic: modafinil binds the transporter slowly and weakly, and a slow rise in occupancy produces a much flatter reinforcement signal than a fast one, which is a general rule across drugs of abuse rather than anything special to this molecule. The other is conformational: modafinil is proposed to stabilise the transporter in a different conformation from cocaine, a so-called atypical inhibitor. That idea is credible and is not proven by anything in the human literature.

A second open question is the trace amine thread. Modafinil did not activate the trace amine receptor TA1 on its own, but it amplified the way phenethylamine activated TA1 in cells that also expressed the dopamine or norepinephrine transporter, and not in cells expressing the serotonin transporter ^[6]. Whether that matters at a human dose is unknown; it is listed here because it is one of the few mechanistic leads that has not been folded into the dopamine story.

Third, and most relevant to anyone reading this for practical reasons: nobody knows what daily long-term use does to a healthy brain. The controlled literature is built on people with narcolepsy, apnoea and shift work disorder, where the comparison is against pathological sleepiness. There is no equivalent body of long-term data on healthy adults using it as a work aid, and the trial durations in the neuroenhancement literature are measured in single doses ^[10].

Modafinil is well absorbed, reaches peak plasma concentration around 2 to 4 hours after a dose, and reaches steady state within 2 to 4 days of daily use. Its kinetics are dose-independent between 200 and 600 mg per day, which is unusual and convenient. Elimination half-life is roughly 12 to 15 hours, and that number is dominated by the longer-lived levorotatory enantiomer; the dextrorotatory one clears far faster. It is cleared mostly by amide hydrolysis in the liver with a smaller cytochrome contribution, and under 10% leaves as unchanged drug ^[9]. See pharmacokinetics for why half-life, not dose, decides when a drug stops being a good idea.

That half-life is the single most actionable fact on this page. A dose taken at noon still has meaningful drug on board at midnight. Sleep debt does not disappear because it was postponed, and the fastest way to make a eugeroic useless is to run it into the night and then need it again the next day because the night was ruined. See sleep and circadian rhythm.

The interaction worth naming explicitly: modafinil induces CYP3A4, mostly in the gut wall, and the two clinically substantive interactions found in formal studies were with ethinylestradiol and triazolam ^[9]. In plain terms, modafinil can lower the plasma level of a combined oral contraceptive enough to matter. It also reversibly inhibits CYP2C19 and suppresses CYP2C9 activity, so warfarin and several antidepressants sit in its blast radius. Compounds that induce or inhibit cytochrome activity are unlikely to move modafinil much in the other direction ^[9].

Armodafinil is the single-enantiomer version: the levorotatory, slower-clearing half of racemic modafinil on its own. Removing the fast-clearing enantiomer flattens the late-afternoon concentration curve rather than raising the peak, which is why it is dosed lower and described as longer-acting rather than stronger ^[9]. There is also a fixed modafinil plus armodafinil presentation sold in some markets, which is chemically a way of re-adding what was removed.

Almost everything sold as a eugeroic is either modafinil, a prodrug of modafinil, a single enantiomer of modafinil, or a structural analogue with no completed human trial. Two genuinely different drugs, solriamfetol and pitolisant, are licensed for the same indication by different routes and are the only members with modern randomised evidence of their own.

Adrafinil deserves a note of its own because it is the one most often bought as a legal substitute. It is a hydroxamic acid that the liver hydrolyses into modafinil, so anyone taking adrafinil is taking modafinil with an extra metabolic step and a slower onset. The caution about liver enzymes follows from that first-pass load rather than from any controlled human study; controlled human data on adrafinil are essentially absent, and the clearest published behavioural evidence sits in aged beagles, where 20 mg/kg improved discrimination learning ^[12]. That is a real result and it is a dog study.

The newer analogues are where the marketing outruns the record. Flmodafinil (bisfluoromodafinil, CRL-40,940) and fluorenol, sold as hydrafinil, are both structurally plausible and neither has a completed published human trial. Being an analogue of a drug that works does not carry the working part across; it carries the shape. See research chemicals for why that gap keeps reappearing.

Two licensed drugs are not modafinil at all. Pitolisant is a histamine H3 inverse agonist; blocking the H3 autoreceptor takes the brake off histamine neurons and raises histamine tone directly, which is the mechanism modafinil only reaches indirectly. In the head-to-head trial it beat placebo on the Epworth scale but failed to establish non-inferiority to modafinil ^[13]. Solriamfetol is an unapologetic dopamine and norepinephrine reuptake inhibitor with no pretence of being anything else; at 150 and 300 mg it added 9.8 and 12.3 minutes to mean sleep latency on the Maintenance of Wakefulness Test against 2.1 minutes for placebo, with headache, nausea, reduced appetite and anxiety as the common adverse events ^[14].

This is the part that gets skipped. Modafinil's licensed indications rest on trials in people with a sleep disorder, where the drug is correcting something. Almost all of the interest in it comes from people with normal sleep who want an edge, and that is a different question with a much weaker answer.

The systematic review that addressed it directly searched for every study of modafinil in healthy, non-sleep-deprived humans from 1990 to 2014 and found a split result ^[10]. On simple testing paradigms, most studies showed better executive function, only about half showed improvement in attention or in learning and memory, and a few showed impaired divergent creative thinking. On more complex assessments, gains in attention, executive function and learning were more consistent. There was no preponderance of side effects and no mood change. The reviewers' own conclusion was partly methodological: much of this literature uses psychometric instruments built to detect deficits in ill populations, which are poorly shaped for detecting gains in healthy ones.

Read that carefully, because it cuts both ways. It is not a null result, and it is not the clean cognitive-enhancement story the drug's reputation implies either. The most defensible summary is that modafinil reliably makes people less sleepy and more able to sustain effort, that executive function benefits most consistently, and that the specific claim of making a rested person smarter is not supported.

Off-label, the strongest signals in the earlier systematic review were for attention deficit disorder, post-anaesthetic sedation, cocaine dependence and withdrawal, and augmentation of antidepressants in depression ^[2]. Those are all populations with a deficit to correct, which is consistent with the pattern above.

And the honest comparison one more time: against 600 mg of caffeine, in the exact scenario people usually reach for it, modafinil was equivalent, not superior ^[11]. What it buys over caffeine is a longer and flatter curve, not a bigger effect.

Dependence potential is not zero, and the framing that it was has not survived. The imaging study that measured accumbens dopamine ended with an explicit warning: because drugs that raise dopamine in the nucleus accumbens have the potential for abuse, and because modafinil use is increasing, awareness of potential abuse and dependence in vulnerable people needs to be heightened ^[5]. That is the drug's own literature, not a critic's reading of it. Modafinil is Schedule IV in the US for a reason. See tolerance and dependence.

Contraceptive failure. CYP3A4 induction lowers ethinylestradiol exposure enough to be flagged in the formal interaction studies ^[9]. This is the interaction that causes real harm and it is the one least likely to come up in a forum thread.

Sleep displacement. A 12 to 15 hour half-life means an afternoon dose is a night-time dose. Chronic partial sleep restriction degrades exactly the executive functions the drug is being taken to support, so a routine that trades sleep for wake time can end up net negative even while each individual day feels productive.

Cardiovascular and psychiatric load. Modafinil is described as well tolerated with a low rate of adverse events across its trial base ^[1][10], and that is a fair summary of the average. It is not a claim about individuals with hypertension, arrhythmia, anxiety disorders or a psychosis history, none of whom are well represented in the trials.

Legal status. Modafinil and armodafinil are prescription-only and scheduled in most jurisdictions; solriamfetol is scheduled; adrafinil and the research-chemical analogues occupy the grey space that exists precisely because they are not the licensed molecule. Buying an unscheduled prodrug of a scheduled drug is a legal distinction, not a pharmacological one. None of this is medical advice.